Bayer Corporation

12/03/2021 | Press release | Distributed by Public on 12/03/2021 00:34

Phase III Investigational Trial of NUBEQA® (darolutamide) in Combination with Docetaxel and Androgen Deprivation Therapy (ADT) Meets Primary Endpoint of Significantly[...]